Yannick Cyr, Fazli K Bozal, José Gabriel Barcia Durán, Alexandra A C Newman, Letizia Amadori, Panagiotis Smyrnis, Morgane Gourvest, Dayasagar Das, Michael Gildea, Ravneet Kaur, Tracy Zhang, Kristin M Wang, Richard Von Itter, P Martin Schlegel, Samantha D Dupuis, Bernard F Sanchez, Ann Marie Schmidt, Edward A Fisher, Coen van Solingen, Chiara Giannarelli, Kathryn J Moore
Atherosclerosis is fueled by a failure to resolve lipid-driven inflammation within the vasculature that drives plaque formation. Therapeutic approaches to reverse atherosclerotic inflammation are needed to address the rising global burden of cardiovascular disease (CVD). Recently, metabolites have gained attention for their immunomodulatory properties, including itaconate, which is generated from the tricarboxylic acid-intermediate cis-aconitate by the enzyme Immune Responsive Gene 1 (IRG1/ACOD1). Here, we tested the therapeutic potential of the IRG1-itaconate axis for human atherosclerosis...
April 9, 2024: Proceedings of the National Academy of Sciences of the United States of America